Stockreport

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Theriva Biologics, Inc.  (TOVX) 
PDF – The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for met [Read more]